Our research
- Development of new treatments for fungal diseases such as cryptococcal meningitis and Candida, in collaboration with Queen's University Belfast and MRC Centre for Medical Mycology at the University of Exeter.
- Understanding resistance liabilities of compounds listed in the WHO Essential Medicines List, in collaboration with CAMO-Net.
- Development of antimicrobial combinations for global cefiderocol based regimens, in collaboration with the Global Antibiotic Research & Development Partnership (GARDP)
- New treatments for neonatal sepsis, in collaboration with the Global Antibiotic Research & Development Partnership (GARDP)
- Development of new experimental platforms for MDR/XDR pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa, in collaboration with iiCON
Key staff
Back to: Institute of Systems, Molecular and Integrative Biology